Vera Therapeutics (VERA) Non-Current Assets (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Non-Current Assets data on file, last reported at $5.9 million in Q1 2026.

• Quarterly Non-Current Assets rose 45.12% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.2 million (up 62.0% YoY) and the FY2025 annual result came in at $5.8 million, up 31.08% from the prior year.
• Non-Current Assets climbed to $5.9 million in Q1 2026, from $5.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $7.2 million in Q1 2022 to a low of $2.5 million in Q2 2024.
• A 5-year average of $5.1 million and a median of $5.2 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 2367.92% — and 2024, when it tumbled 44.26%.
• Tracing VERA's Non-Current Assets over 5 years: stood at $5.7 million in 2022, then tumbled by 38.59% to $3.5 million in 2023, then grew by 26.68% to $4.5 million in 2024, then surged by 31.08% to $5.8 million in 2025, then advanced by 1.49% to $5.9 million in 2026.
• The last three Non-Current Assets figures came in at $5.9 million (Q1 2026), $5.8 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.